ANNUAL BURDEN ESTIMATES

<table>
<thead>
<tr>
<th>Instrument</th>
<th>Number of responses per respondent</th>
<th>Average burden hours per response</th>
<th>Total burden hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Medical Support Notice</td>
<td>97,775</td>
<td>0.17</td>
<td>892,574.50</td>
</tr>
</tbody>
</table>

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Proposed Collection: Comment Request; Brain Power! The NIDA Junior Scientist Program and the Companion Program, Brain Power! Challenge

SUMMARY: In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for the opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

Proposed Collection: Title: Brain Power! The NIDA Junior Scientist Program, for grades K–5, and the companion program for Middle School, the Brain Power! Challenge.

Type of Information Collection Request: NEW.

Need and Use of Information Collection: This is a request for clearance to evaluate the effectiveness of the Brain Power! Program’s ability to:

- Increase students’ knowledge about the biology of the brain and the neurobiology of drug addiction;
- Increase positive attitudes toward science careers in science, and science as an enjoyable endeavor, and stimulating interest in scientific careers; and
- Promote more balanced perceptions and attitudes of scientists of many races, ages, and genders

The secondary goal is to determine the influence or change of attitudes toward and intentions about drug use. The findings will provide valuable information concerning the goals of NIDA’s Science Education Program of increasing scientific literacy and stimulating interest in scientific careers. In order to test the effectiveness of the evaluation, information will be collected from students before and after exposure to the curriculum with pre- and post-test self-report measures.

Surveys also will be administered to teachers after the completion of the program to examine ease and fidelity of implementation, as well as impact in knowledge and understanding of the neurobiology of addiction. Surveys will be administered to parents to obtain parental reaction and opinion on the materials and the degree to which parents find the curriculum informative and appropriate.

Frequency of Response: On occasion.

Affected Public: Middle school students, teachers, and parents.

Type of Respondents: Students, Teachers, and Parents. The reporting burden is as follows: Estimated Number of Respondents: 1,260.

Estimated Number of Responses per Respondent: Students: 2, Parents and Teachers: 1.

Average Burden Hours per Response: Students: .5, Parents: 2.5 and Teachers: .5.

Estimated Total Annual Burden Hours Requested: 892.5. There are no Capital Costs to report. There are no Operating or Maintenance Costs to report. The estimated annualized burden is summarized below.

<table>
<thead>
<tr>
<th>Types of respondents</th>
<th>Number of respondents</th>
<th>Frequency of response</th>
<th>Average time per response</th>
<th>Annual hour burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Students (K–grade 5)</td>
<td>375</td>
<td>2</td>
<td>.5</td>
<td>375</td>
</tr>
<tr>
<td>Students (grades 6–9)</td>
<td>375</td>
<td>2</td>
<td>.5</td>
<td>375</td>
</tr>
<tr>
<td>Parents (survey) (K–grade 5)</td>
<td>25</td>
<td>1</td>
<td>.25</td>
<td>62.5</td>
</tr>
<tr>
<td>Parents (survey) (grades 6–9)</td>
<td>25</td>
<td>1</td>
<td>.25</td>
<td>62.5</td>
</tr>
<tr>
<td>Parents (postcard) (K–grade 5)</td>
<td>200</td>
<td>1</td>
<td>.25</td>
<td>50</td>
</tr>
<tr>
<td>Parents (postcard) (grades 6–9)</td>
<td>200</td>
<td>1</td>
<td>.25</td>
<td>50</td>
</tr>
<tr>
<td>Teachers (evaluation)</td>
<td>30</td>
<td>1</td>
<td>.5</td>
<td>15</td>
</tr>
<tr>
<td>Teachers (online survey)</td>
<td>30</td>
<td>1</td>
<td>.5</td>
<td>15</td>
</tr>
<tr>
<td>Total</td>
<td>1,260</td>
<td></td>
<td></td>
<td>892.50</td>
</tr>
</tbody>
</table>
Request for Comments: Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points:

1. Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility;
2. The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
3. Ways to enhance the quality, utility, and clarity of the information to be collected; and
4. Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

FOR FURTHER INFORMATION CONTACT: To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Cathrine Sasek, Coordinator, Science Education Program, Office of Science Policy and Communications, National Institute on Drug Abuse, 6001 Executive Blvd, Room 5257, Bethesda, MD 20892, or call non-toll-free number (301) 443–6071; fax (301) 443–6277; or by e-mail to csasek@nida.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 60-days of the date of this publication.


Mary Affeldt,
Executive Officer, (OM Director, NIDA),
National Institutes of Health.

[FR Doc. 2010–15608 Filed 6–25–10; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
[Docket No. FDA–2010–N–0001]

Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory Committee.

General Function of the Committee:
To provide advice and recommendations to the agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on July 27, 2010, from 8 a.m. to 6 p.m.

Location: Holiday Inn, Ballroom, 2 Montgomery Village Ave., Gaithersburg, MD.

Contact Person: Tracy Phillips, Food and Drug Administration, Center for Devices and Radiological Health, 10903 New Hampshire Ave., Bldg. 66, rm. 1611, Silver Spring, MD 20993–0002, 301–796–6150 or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 3014512521. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Agenda: On July 27, 2010, the committee will discuss, make recommendations and vote on a premarket approval application for the AMPLIFY rhBMP-2 Matrix, sponsored by Medtronic, Inc. The AMPLIFY rhBMP-2 Matrix is used for posterolateral fusion treatment of single level lumbar (L2–S1) degenerative disc disease.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before July 21, 2010. Oral presentations from the public will be scheduled between approximately 1 and 2 p.m., immediately following lunch.

Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before July 13, 2010. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by July 14, 2010.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact AnnMarie Williams, Conference Management Staff, 301–796–5066, at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: June 18, 2010.

Thinh Nguyen,
Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2010–15350 Filed 6–23–10; 4:15 pm]
BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections